Equillium Inc
NASDAQ:EQ

Watchlist Manager
Equillium Inc Logo
Equillium Inc
NASDAQ:EQ
Watchlist
Price: 0.7871 USD -1.61%
Market Cap: 27.9m USD

EV/EBIT
Enterprise Value to EBIT

-0.4
Current
-0.1
Median
3.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-0.4
=
Enterprise Value
2.5m USD
/
EBIT
-6.8m USD
Market Cap EV/EBIT
US
Equillium Inc
NASDAQ:EQ
27.9m USD -0.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -208 527.2
US
Abbvie Inc
NYSE:ABBV
371.2B USD 25.8
US
Amgen Inc
NASDAQ:AMGN
167.2B USD 29.2
US
Gilead Sciences Inc
NASDAQ:GILD
132.3B USD 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.1B USD 27.9
US
Epizyme Inc
F:EPE
94.1B EUR -521.3
AU
CSL Ltd
ASX:CSL
123B AUD 21.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.1B USD 11.9
US
Seagen Inc
F:SGT
39.3B EUR -55.3
NL
argenx SE
XBRU:ARGX
34B EUR -2 413.4
EBIT Growth EV/EBIT to Growth
US
Equillium Inc
NASDAQ:EQ
Average EV/EBIT: 21.7
Negative Multiple: -0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 527.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.8
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.2
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.9
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.8
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.9
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 413.4 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-0.2
2-Years Forward
EV/EBIT
-0.1
3-Years Forward
EV/EBIT
-0